TFX Stock Recent News
TFX LATEST HEADLINES
Teleflex's (TFX) first-quarter 2024 results reflect growth across the majority of the company's product families in EMEA.
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teleflex (TFX) came out with quarterly earnings of $3.21 per share, beating the Zacks Consensus Estimate of $3.07 per share. This compares to earnings of $3.09 per share a year ago.
Teleflex reported a better-than-expected first-quarter profit on Thursday, on the back of strong demand for its medical devices.
Evaluate the expected performance of Teleflex (TFX) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the BofA Securities 2024 Health Care Conference at the Encore Hotel in Las Vegas, Nevada, on Tuesday, May 14, 2024, at 2:20 p.m. (PT).
WAYNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 2, 2024.
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.
Teleflex (TFX) surpasses earnings and revenue estimates in the fourth quarter of 2023.